

Pan European patient group funding

The European Federation of Allergy and Airways Diseases Patients Associations (EFA)

EFA is a European network of allergy, asthma and COPD patient organisations that was founded in 1991, prompted by the belief that an international organisation formed by European patients associations that share the same aims would be a more effective way to serve the needs and safeguard the rights of patients and their carers.

We have supported this organisation since 1997.

During 2019:

- We provided €30,000 core membership to support the group in delivering its objectives.
- We provided €30,000 for the Patient Challenge project to raise the profile of allergy, asthma and COPD in the EU and the needs of patients suffering from them.
- We provided €20,000 for capacity building and enabling EFA and its members to exchange knowledge and contribute to EU and international level campaigns
- We provided €1,365 for attendance at GSK's Patient Advocacy Advisory Board (PAAB). We also provided travel and accommodation for this meeting.
- We provided €1,200 for attendance at GSK's European Health Advisory Board (HAB). We also provided travel and accommodation for this meeting.

Our support represented **9.3%** of their overall income.

During 2018:

- We provided €30,000 core membership to support the group in delivering its objectives.
- We provided €40,000 for Active Patient Access Survey in seven European countries, on asthma and COPD diagnosis and treatment.
- We provided €30,000 for Severe Asthma Awareness campaign.
- We provided €1,200 for attendance at GSK's Patient Advocacy Advisory Board (PAAB).
- We provided €600 for attendance at GSK's European Health Advisory Board (HAB). We also provided travel and accommodation for this meeting.

Our support represents 8.75% of their overall income.

During 2017:

- We provided an unrestricted grant of €30,000 to support the group in delivering its objectives.
- We also provided €40,000 to support EFA's COPD Move project consisting of patient videos aimed at raising awareness about the benefit that active COPD patients have and motivate other patients

Our support represents 7.6% of their overall income.